BHK-21细胞蛋白样品双向凝胶电泳条件的优化

分别从BHK-21细胞处理方法、样品上样量、聚丙烯酰胺凝胶浓度和染色方法4个方面优化了BHK-21细胞蛋白双向凝胶电泳的技术条件,以为口蹄疫病毒感染细胞比较蛋白质组学研究奠定基础。结果表明,处理细胞时,采用超声破碎方法优于反复冻融方法;用考马斯亮蓝染色时,7cm胶条上样量为100μg时图谱的蛋白点较多且分离清晰;浓度为10%的聚丙烯酰胺凝胶所得的蛋白点较多;通过2种染色方法的比较,硝酸银染色方法优于考马斯亮蓝染色方法。优化后的双向凝胶电泳技术得到的图谱,蛋白点多且清晰,重复性好,拖尾现象减少,符合软件分析的要求,可用于口蹄疫病毒感染BHK-21细胞蛋白质组学研究。     

猪繁殖与呼吸综合征病毒的免疫学研究进展

从猪繁殖与呼吸综合征病毒的主要抗原蛋白、持续性感染、细胞免疫、体液免疫和免疫抑制几方面论述了猪繁殖与呼吸综合征病毒与宿主之间存在复杂的免疫相互作用,旨在为猪繁殖与呼吸综合征疫苗的设计与研制提供新的思路和方法。     

Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule

The Food and Drug Administration (FDA) is amending the final monograph (FM) for over-the-counter (OTC) bronchodilator drug products to add additional warnings (e.g., an "Asthma alert') and to revise the indications, warnings, and directions in the labeling of products containing the ingredients ephedrine, ephedrine hydrochloride, ephedrine sulfate, epinephrine, epinephrine bitartrate, racephedrine hydrochloride, and racepinephrine hydrochloride. FDA is issuing this final rule after considering data and information submitted in response to the Agency's proposed labeling revisions for these products. This final rule is part of FDA's ongoing review of OTC drug products.     

Required warnings for cigarette packages and advertisements. Final rule

The Food and Drug Administration (FDA) is amending its regulations to add a new requirement for the display of health warnings on cigarette packages and in cigarette advertisements. This rule implements a provision of the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) that requires FDA to issue regulations requiring color graphics, depicting the negative health consequences of smoking, to accompany the nine new textual warning statements required under the Tobacco Control Act. The Tobacco Control Act amends the Federal Cigarette Labeling and Advertising Act (FCLAA) to require each cigarette package and advertisement to bear one of nine new textual warning statements. This final rule specifies the color graphic images that must accompany each of the nine new textual warning statements.     

Medicaid program; payment adjustment for provider-preventable conditions including health care-acquired conditions. Final rule

This final rule will implement section 2702 of the Patient Protection and Affordable Care Act which directs the Secretary of Health and Human Services to issue Medicaid regulations effective as of July 1, 2011 prohibiting Federal payments to States under section 1903 of the Social Security Act for any amounts expended for providing medical assistance for health care-acquired conditions specified in the regulation. It will also authorize States to identify other provider-preventable conditions for which Medicaid payment will be prohibited.     

Medical Devices; general and plastic surgery devices; classification of contact cooling system for aesthetic use. Final rule

The Food and Drug Administration (FDA) is classifying the contact cooling system for aesthetic use into class II (special controls). The special control that will apply to the device is the guidance document entitled "Guidance for Industry and FDA Staff; Class II Special Controls Guidance Document: Contact Cooling System for Aesthetic Use." The Agency is classifying the device into class II (special controls) in order to provide reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document that will serve as the special control for this device type.     

Medical devices; reclassification of the topical oxygen chamber for extremities. Final rule

The Food and Drug Administration (FDA) is reclassifying the topical oxygen chamber for extremities (TOCE) from class III to class II. This device is intended to surround a patient's limb and apply humidified oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers, such as bedsores. This reclassification is on the Secretary of Health and Human Services's own initiative based on new information. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) as amended by the Medical Device Amendments of 1976 (the 1976 Amendments), the Safe Medical Devices Act of 1990 (the SMDA), and the Food and Drug Administration Modernization Act of 1997 (FDAMA). Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document entitled ``Class II Special Controls Guidance Document: Topical Oxygen Chamber for Extremities,' which will serve as the special control for this device.     

Medical devices; general and plastic surgery devices; classification of the low level laser system for aesthetic use. Final rule

The Food and Drug Administration (FDA) is classifying the low level laser system for aesthetic use into class II (special controls). The special control(s) that will apply to the device is entitled ``Class II Special Controls Guidance Document: Low Level Laser System for Aesthetic Use.' The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document that will serve as the special control for this device type.     

Advisory committee; Medical Imaging Drugs Advisory Committee; re-establishment

The Food and Drug Administration (FDA) is announcing the re-establishment of the Medical Imaging Drugs Advisory Committee in FDA's Center for Drug Evaluation and Research. This rule amends the current language for the Medical Imaging Drugs Advisory Committee in the Agency's list of standing advisory committees in FDA's regulations.     

Nachhaltige Bioenergie – Instrumente zur Vermeidung negativer indirekter Landnutzungseffekte

Indirekte Landnutzungs?nderungen beim Anbau von Energiepflanzen k?nnen die Treibhausgasminderungsbilanz von Energie aus Biomasse herabsetzen und Biodiversit?t sowie Boden- und Wasserressourcen beeintr?chtigen. Um derartige Effekte in rechtliche Regelungen über die Nachhaltigkeit von Bioenergie einzubeziehen, wurden verschiedene Ans?tze vorgeschlagen. Eine überzeugende Methodologie steht bis heute jedoch noch nicht zur Verfügung. Der Beitrag gibt einen überblick über die diskutierten Methoden, bietet eine vergleichende Bewertung und leitet hieraus rechtspolitische Empfehlungen ab.